Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 17/20 | 0.63 |
| ▸ | ACACA | Q13085 | 12/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3497990 | 0.90 | ACACB (0.64) | ACACBACACACYP2C9KDM4E | |
| SCHEMBL3498282 | 0.90 | ACACB (0.65) | ACACBACACACYP2C9KDM4E | |
| SCHEMBL3496875 | 0.90 | ACACB (0.65) | ACACBACACACYP2C9KDM4E | |
| SCHEMBL3497235 | 0.90 | ACACB (0.64) | ACACBACACACYP2C9KDM4E | |
| SCHEMBL3496432 | 0.88 | ACACB (0.63) | ACACBACACACYP2C9KDM4E | |
| SCHEMBL3497762 | 0.87 | ACACB (0.61) | ACACBACACAKDM4E | |
| SCHEMBL13312156 | 0.86 | ACACB (0.70) | ACACBACACACYP2C9 | |
| SCHEMBL3496368 | 0.85 | ACACB (0.69) | ACACBACACACYP2C9 | |
| SCHEMBL3497823 | 0.85 | ACACB (0.69) | ACACBACACACYP2C9 | |
| SCHEMBL3497814 | 0.85 | ACACB (0.59) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | ACACA, CPT1B, PC | ACACB 6/4885ACACA 1/4885ALDH1A1 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.